Global Phase III Study of Datopotamab Deruxtecan With or Without Rilvegostomig Compared to Pembrolizumab as First-Line Treatment for Advanced Non-Squamous NSCLC With High PD-L1 Expression
Led by AstraZeneca · Updated on 2026-10-28
675
Participants Needed
290
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type.
Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options.
During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.
CONDITIONS
Brief Title
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Dato‑DXd plus Rilvegostomig (Investigational)
Rilvegostomig monotherapy (Investigational)
Pembrolizumab monotherapy (Comparator)
What it is
Investigational antibody‑drug conjugate plus bispecific PD‑1/TIGIT blocker combination tested in first‑line advanced non‑squamous NSCLC with PD‑L1 ≥50%
Investigational bispecific PD‑1/TIGIT antibody monotherapy tested in same population
Active comparator: PD‑1 inhibitor pembrolizumab monotherapy, current immunotherapy option
Role in the trial
Experimental combination arm
Experimental monotherapy arm
Comparator arm representing standard immunotherapy
Primary use
First‑line treatment in PD‑L1 high, EGFR/ALK/ROS1‑negative advanced NSCLC
First‑line treatment in same population
Standard first‑line immunotherapy for PD‑L1 ≥50% NSCLC
Administration
Dato‑DXd and rilvegostomig delivered intravenously per trial protocol
Rilvegostomig given intravenously per trial protocol
Pembrolizumab administered intravenously per standard dosing
Evidence status
Efficacy & safety are being evaluated in ongoing Phase III trial
Being evaluated in same ongoing Phase III trial
Long‑term effectiveness established in PD‑L1 ≥50% NSCLC real‑world studies
Important risks
Safety is under investigation in the trial; profile not yet established
Safety is under investigation; profile not yet established
Adverse events profile is well known from prior and real‑world data
Important limitations
No efficacy or safety results yet; investigational combination
Efficacy and safety data are not yet available
Response may vary; not all patients achieve long‑term control
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Histologically or cytologically confirmed non-squamous NSCLC.
Stage IIIB, IIIC, or IV metastatic NSCLC not suitable for surgery or chemoradiation.
No sensitising EGFR mutations, ALK or ROS1 rearrangements, or other actionable genomic alterations.
Must provide tumor sample for PD-L1, TROP2, and other biomarker testing.
Tumor PD-L1 expression of 50% or higher.
At least one measurable lesion not previously treated with radiation.
ECOG performance status of 0 or 1.
Adequate bone marrow and organ function.
You will not qualify if you...
Prior systemic therapy for advanced or metastatic NSCLC.
Squamous or predominantly squamous NSCLC, mixed small cell lung cancer, or sarcomatoid variant.
History of another primary cancer within 3 years.
Active or previous autoimmune or inflammatory disorders (with exceptions).
Severe or uncontrolled diseases affecting study participation.
Significant fluid retention not manageable with drainage.
History or current interstitial lung disease or pneumonitis.
Significant lung function impairment.
Untreated or unstable brain metastases or spinal cord compression.
History of leptomeningeal carcinomatosis.
Significant corneal disease.
Active infections including TB, hepatitis, or uncontrolled HIV.
History of primary immunodeficiency.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to several years as determined by study progress
Participants receive one of three study treatments by intravenous infusion every three weeks: Datopotamab Deruxtecan with Rilvegostomig, Rilvegostomig alone, or Pembrolizumab alone.
Infusions every 3 weeks on Day 1 of each 21-day cycle
Follow-up
Duration - Approximately 4 to 6 years
Participants are monitored for progression-free survival, overall survival, and other health outcomes with regular assessments and questionnaires.
Regular follow-up visits over several years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Using 3-D Virtual Lung Resection to Predict Lung Function After VATS Surgery for Non-Small Cell Lung Cancer
Early Evaluation of Neoadjuvant Immunotherapy Response
Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer
Patients Aged 18 to 75 Years
Evaluating Calderasib with Subcutaneous Pembrolizumab Versus Pembrolizumab Plus Chemotherapy
for KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
Randomized Study of Adjuvant Cemiplimab Versus Observation in Patients With Surgically Removed Stage II-IIIA Non-Small Cell Lung Cancer Without Prior Chemotherapy
Evaluating Adjuvant Intismeran With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa Compared to Placebo in High-Risk Stage I Non-Small Cell Lung Cancer
Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in People With Locally Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer After Chemoradiotherapy
Phase 2 Study of TQB2102 Injection for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with HER2 Gene Abnormality
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Testing Safety and Effectiveness of BNT326 and Pumitamig Combination Therapy in Advanced Non-small Cell Lung Cancer
Phase IIIb Study to Evaluate the Safety and Effectiveness of Vebreltinib PLB1001 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having MET Exon 14 Mutation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.
Thomas Newsom-Davis, Barbara Melosky, Rebecca S Heist...